With the help of funding provided by Baron & Budd, Dr. David Sugarbaker launched the prestigious International Mesothelioma Program (IMP) at Brigham and Women’s Hospital.
Page from the IMP Annual Report featuring Russell Budd and Dr. David Sugarbaker. Baron & Budd served on the inaugural Executive Advisory Board of the organization.
The International Mesothelioma Program, or IMP, works toward offering top-quality care and researching advanced treatment options for the most common type of mesothelioma, malignant pleural mesothelioma. The IMP offers a variety of research, support and clinical trial programs, with an intensive focus on the development of cutting-edge mesothelioma treatments. IMP is not only a world leader in research, it is also one of the largest programs of its kind in the world. The organization is a collaboration between Harvard Medical School, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital.
The IMP’s mission is to work toward creating more effective treatment techniques, as well as more effective medications, for malignant pleural mesothelioma. This work is being performed to help extend the quality of life for mesothelioma patients. In addition, IMP is keenly aware that there is a substantial need for stronger tools for earlier screening of mesothelioma and has taken significant strides forward in this area.
Dr. Sugarbaker has gained a substantial amount of notoriety for his work on extrapleural pneumonectomy (EPP) or pleurectomy surgery combined with intrathoracic/intraperitoneal heated chemotherapy.